Q-omics provides the consensus-scored CHST13 profile across patient tissues and cancer cell-line models. CHST13 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, CHST13 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, CHST13 RNA expression shows 13,032 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UVM, KIRC, and TGCT as cancer lineages where CHST13 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CHST13 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CHST13 survival associations across molecular data types. CHST13 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (5) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CHST13 RNA expression–survival associations across cancer types. High CHST13 expression shows unfavorable associations in UVM, UCEC, LIHC and LUAD, but favorable associations in KIRP and DLBC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for CHST13 RNA expression.
This table summarizes CHST13 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for CHST13. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CHST13 shows lower tumor expression in KICH and higher tumor expression in KIRC, THCA, HNSC, STAD and LIHC. The KIRC box plot shows higher CHST13 RNA expression in tumor versus normal tissue (log2 FC = +2.785, t-test p < 0.001).
This table shows molecular features associated with CHST13 in patient tissues and cancer cell lines. In patient samples, CHST13 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, CHST13 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
